Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: 48X005
MIFTS: 37

48,xyyy

Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases
Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for 48,xyyy

About this section

MalaCards integrated aliases for 48,xyyy:

Name: 48,xyyy 53
48,xyyy Syndrome 59

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Neuronal diseases Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases
Rare infertility disorders
Developmental anomalies during embryogenesis


External Ids:

ICD10 via Orphanet 34 Q98.8
Orphanet 59 ORPHA99329
Sources

Summaries for 48,xyyy

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 99329Definition48,XYYY syndrome is a rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to radioulnar synostosis and hypogonadotropic hypogonadism. The drugs Nitric Oxide and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and liver, and related phenotypes are hypertelorism and short neck

Sources

Related Diseases for 48,xyyy

About this section

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 radioulnar synostosis 10.2
2 hypogonadotropic hypogonadism 10.2

Sources

Symptoms & Phenotypes for 48,xyyy

About this section

Human phenotypes related to 48,xyyy:

59 32 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertelorism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000316
2 short neck 59 32 hallmark (90%) Very frequent (99-80%) HP:0000470
3 high palate 59 32 hallmark (90%) Very frequent (99-80%) HP:0000218
4 global developmental delay 59 32 hallmark (90%) Very frequent (99-80%) HP:0001263
5 depressed nasal bridge 59 32 hallmark (90%) Very frequent (99-80%) HP:0005280
6 delayed speech and language development 59 32 hallmark (90%) Very frequent (99-80%) HP:0000750
7 pes planus 59 32 hallmark (90%) Very frequent (99-80%) HP:0001763
8 intellectual disability, mild 59 32 hallmark (90%) Very frequent (99-80%) HP:0001256
9 long philtrum 59 32 hallmark (90%) Very frequent (99-80%) HP:0000343
10 feeding difficulties 59 32 hallmark (90%) Very frequent (99-80%) HP:0011968
11 thick lower lip vermilion 59 32 hallmark (90%) Very frequent (99-80%) HP:0000179
12 recurrent upper respiratory tract infections 59 32 hallmark (90%) Very frequent (99-80%) HP:0002788
13 epicanthus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000286
14 acne 59 32 hallmark (90%) Very frequent (99-80%) HP:0001061
15 abnormal dermatoglyphics 59 32 hallmark (90%) Very frequent (99-80%) HP:0007477
16 male hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000026
17 aggressive behavior 59 32 hallmark (90%) Very frequent (99-80%) HP:0000718
18 asthma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002099
19 azoospermia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000027
20 radioulnar synostosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002974
21 tall stature 59 32 hallmark (90%) Very frequent (99-80%) HP:0000098
22 impulsivity 59 32 hallmark (90%) Very frequent (99-80%) HP:0100710
23 abnormal renal morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0012210
24 primary gonadal insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0008193
25 dislocated radial head 59 32 hallmark (90%) Very frequent (99-80%) HP:0003083
26 hypoplasia of dental enamel 59 32 hallmark (90%) Very frequent (99-80%) HP:0006297
27 low frustration tolerance 59 32 hallmark (90%) Very frequent (99-80%) HP:0000744
28 irregularly spaced teeth 59 32 hallmark (90%) Very frequent (99-80%) HP:0006316
29 intellectual disability 59 Very frequent (99-80%)
30 behavioral abnormality 59 Very frequent (99-80%)
31 abnormality of the foot 59 Very frequent (99-80%)
Sources

Drugs & Therapeutics for 48,xyyy

About this section

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1673)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Amantadine Approved Phase 4 768-94-5 2130
3
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
4
Digoxin Approved Phase 4 20830-75-5 30322 2724385
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
7
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
8
Riociguat Approved Phase 4 625115-55-1
9
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
10
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
11
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
12
Hexetidine Approved, Investigational Phase 4 141-94-6
13
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
14
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
15
Trimetazidine Approved, Investigational Phase 4 5011-34-7
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
18
leucovorin Approved Phase 4 58-05-9 143 6006
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
21
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
22
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
23
Nifedipine Approved Phase 4 21829-25-4 4485
24
Saw palmetto Approved, Experimental, Investigational Phase 4
25
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
26
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
27
Ranibizumab Approved Phase 4 347396-82-1 459903
28
Montelukast Approved Phase 4 158966-92-8 5281040
29
Eplerenone Approved Phase 4 107724-20-9 150310 443872
30
Norepinephrine Approved Phase 4 51-41-2 439260
31
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
32
Dalteparin Approved Phase 4 9005-49-6
33
Pamidronate Approved Phase 4 40391-99-9 4674
34
Omalizumab Approved, Investigational Phase 4 242138-07-4
35
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
36
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
37
Natalizumab Approved, Investigational Phase 4 189261-10-7
38
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
39
Orphenadrine Approved Phase 4 83-98-7 4601
40
Insulin Lispro Approved Phase 4 133107-64-9
41
Tavaborole Approved, Investigational Phase 4 174671-46-6
42
Dezocine Approved, Investigational Phase 4 53648-55-8 3033053 40841
43
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
44
Fosamprenavir Approved Phase 4 226700-79-4 131536
45
Nefopam Approved, Investigational Phase 4 13669-70-0
46
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
47
Desogestrel Approved Phase 4 54024-22-5 40973
48
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
49
Etanercept Approved, Investigational Phase 4 185243-69-0
50
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
2 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
6 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
7 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
8 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
9 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
10 The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial Unknown status NCT01339065 Phase 4 Ketamine
11 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
12 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
13 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
14 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
15 Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery. Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
16 Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine Unknown status NCT01256866 Phase 4 Dexmedetomidine;Midazolam
17 Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification Unknown status NCT01546974 Phase 4
18 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
19 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
20 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
21 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
22 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
23 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
24 Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw Unknown status NCT01219088 Phase 4 Bupivacaine, morphine
25 A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
26 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
27 Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA) Unknown status NCT01698203 Phase 4 ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun);Placebo;ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
28 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
29 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
30 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
31 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
32 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
33 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
34 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
35 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
36 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
37 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
38 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
39 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
40 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
41 Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595 Unknown status NCT02367599 Phase 4 Vitamin D Supplement
42 Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically Unknown status NCT02355093 Phase 4 ropivacaine
43 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
44 Antibiotic Prophylaxis in Prosthetic Breast Reconstructions Unknown status NCT02012517 Phase 4 Prolonged antibiotic treatment;Short antibiotic course (standard of care)
45 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
46 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
47 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
48 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
49 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
50 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine

Search NIH Clinical Center for 48,xyyy

Sources

Genetic Tests for 48,xyyy

About this section
Sources

Anatomical Context for 48,xyyy

About this section

MalaCards organs/tissues related to 48,xyyy:

41
Testes, Lung, Liver, Brain, Kidney, Breast, Heart
Sources

Publications for 48,xyyy

About this section

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Comparative evaluation of hesperetin loaded nanoparticles for anticancer activity against C6 glioma cancer cells. 38
30688095 2019
2
Transplantation of autologous bone marrow-derived mesenchymal stem cells under arthroscopic surgery with microfracture versus microfracture alone for articular cartilage lesions in the knee: A multicenter prospective randomized control clinical trial. 38
31312692 2019
3
Preclinical studies of toxicity and safety of the AS-48 bacteriocin. 38
31360546 2019
4
Early prediction of treatment failure in severe community-acquired pneumonia: The PRoFeSs score. 38
31177029 2019
5
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. 38
31199513 2019
6
Bacterial cellulose/hyaluronic acid nanocomposites production through co-culturing Gluconacetobacter hansenii and Lactococcus lactis in a two-vessel circulating system. 38
31295575 2019
7
Carriage of carbapenemase- and extended-spectrum cephalosporinase-producing Escherichia coli and Klebsiella pneumoniae in humans and livestock in rural Cambodia; gender and age differences and detection of blaOXA-48 in humans. 38
31264805 2019
8
Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. 38
31180906 2019
9
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. 38
31352829 2019
10
Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: Results of a prospective and multicenter study. 38
31297894 2019
11
Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study. 38
31131528 2019
12
Sigma-1 Receptor Expression in DRG Neurons During a Carrageenan-Provoked Inflammation. 38
30614637 2019
13
Inactivation effect of marination liquids prepared with koruk juice and dried koruk pomace on Salmonella Typhimurium, Escherichia coli O157:H7 and Listeria monocytogenes inoculated on meat. 38
31152975 2019
14
Yeast β-glucans and microalgal extracts modulate the immune response and gut microbiome in Senegalese sole (Solea senegalensis). 38
31128296 2019
15
Effects of Dietary Clostridium butyricum on the Growth, Digestive Enzyme Activity, Antioxidant Capacity, and Resistance to Nitrite Stress of Penaeus monodon. 38
29858778 2019
16
Interobserver variability impairs radiologic grading of primary graft dysfunction after lung transplantation. 38
31204131 2019
17
Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. 38
31017476 2019
18
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Closure of Myelomeningocele Within 48 Hours to Decrease Infection Risk. 38
31418041 2019
19
Lung ultrasound features of children with complicated and noncomplicated community acquired pneumonia: A prospective study. 38
31264383 2019
20
Molecular Response of Rabbit Menisci to Surgically Induced Hemarthrosis and a Single Intra-Articular Dexamethasone Treatment. 38
31095777 2019
21
Phytotoxicity and oxidative stress of perfluorooctanesulfonate to two riparian plants: Acorus calamus and Phragmites communis. 38
31100588 2019
22
Inhibitory action of thymol on fecal microbial activity in Tamandua tetradactyla and its effect on glucocorticoid metabolite measurement. 38
31002827 2019
23
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. 38
31355323 2019
24
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. 38
31165191 2019
25
Randomised study comparing heart rate measurement in newly born infants using a monitor incorporating electrocardiogram and pulse oximeter versus pulse oximeter alone. 38
30425114 2019
26
Detection of Reg3γ by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats. 38
31404030 2019
27
Systematic review of cigars, cigarillos, and little cigars among adolescents: Setting research agenda to inform tobacco control policy. 38
31125939 2019
28
Post-treatment of Fungal Biomass to Enhance Pigment Production. 38
30957195 2019
29
A selective culture medium for screening linezolid-resistant gram-positive bacteria. 38
30981556 2019
30
Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy. 38
31165962 2019
31
Porcine blastocyst viability and developmental potential is maintained for 48 h of liquid storage at 25 °C without CO2 gassing. 38
31200096 2019
32
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks. 38
31272264 2019
33
[Reduction of needlestick injuries by 48 % in 1 year : Effects of improvement of the safety concept according to the European Union Council directive 2010/32/EU at a large regional hospital]. 38
31428806 2019
34
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48. 38
31415381 2019
35
Correction: Cyaphide-alkynyl complexes: metal-ligand conjugation and the influence of remote substituents. 38
31414091 2019
36
Identification of a novel allele, HLA-B*51:01:41, in a platelet donor by sequence-based typing. 38
31373778 2019
37
Is there a relation between sudden sensorineural hearing loss and white matter lesions? 38
31410545 2019
38
Dose-dependent pruritogenic and inflammatory effects of intradermal injections of histamine, compound 48/80 and anti-canine IgE in healthy dogs. 38
31038263 2019
39
The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region. 38
31402295 2019
40
Metagenome-Assembled Genome Sequence of Phormidium sp. Strain SL48-SHIP, Isolated from the Microbial Mat of Salt Lake Number 48 (Novosibirsk Region, Russia). 38
31371542 2019
41
Associations between patient and system characteristics and MET review within 48 h of admission to a teaching hospital: A retrospective cohort study. 38
31155230 2019
42
Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis. 38
31385145 2019
43
Corrigendum to "Fabrication of chitin-chitosan/nano TiO2-composite scaffolds for tissue engineering applications" [Int. J. Biol. Macromol. 48 (2011) 336-344]. 38
31256977 2019
44
Corrigendum to "Fabrication of chitosan/poly(caprolactone) nanofibrous scaffold for bone and skin tissue engineering" [Int. J. Biol. Macromol. 48 (2011) 571-576]. 38
31076183 2019
45
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. 38
30985556 2019
46
Inhibitory effect of rapamycin on proliferation of human umbilical arterial smooth muscle cells. 38
31232124 2019
47
Nasal double DNA adjuvant induces salivary FimA-specific secretory IgA antibodies in young and aging mice and blocks Porphyromonas gingivalis binding to a salivary protein. 38
31426773 2019
48
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. 38
31382177 2019
49
Application of peripherally inserted central catheters in critically ill newborns experience from a neonatal intensive care unit. 38
31393341 2019
50
Aluminum stress differentially affects physiological performance and metabolic compounds in cultivars of highbush blueberry. 38
31375763 2019
Sources

Variations for 48,xyyy

About this section
Sources

Expression for 48,xyyy

About this section
Search GEO for disease gene expression data for 48,xyyy.
Sources

Pathways for 48,xyyy

About this section
Sources

GO Terms for 48,xyyy

About this section
Sources

Sources for 48,xyyy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....